Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) announced additional data from its Phase 3 TRANSCEND trial of setmelanotide in patients with acquired ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE